Results: With a single exception, in heterozygotes for heparin-binding site defect (n = 20), anti-FIIa activities remained in the reference interval, while anti-FXa activities were uniformly decreased. In individuals who were homozygous for heparin-binding site mutation (n = 9), anti-FIIa activities were in
the range of 48% to 80%; the range of anti-FXa activities was 9% to 25%. Anti-FIIa and anti-FXa activities in type I deficiencies and type II pleiotropic deficiency did not differ significantly.
Conclusions: Anti-FXa antithrombin assay is recommended as a first-line test to detect type II heparinbinding site antithrombin deficiency.
Antithrombin (AT) is a member of the serine protease inhibitor (serpin) family and is a key regulator of the coagulation system. 1-3 A prominent feature of AT is its high affinity binding to negatively charged glycosaminoglycans, heparin, or heparan sulfate, which contain specific pentasaccharide units. The main physiologic function of AT is to inactivate activated coagulation factor X (FXa) and thrombin (FIIa). It also inhibits other active clotting factors, like FIXa, FXIa, FXIIa, and FVIIa complexed with tissue factor. AT is a progressive inhibitor, the rate of its reaction with the active coagulation factors is slow, but in the presence of heparin or heparan sulfate, the rate of inhibition is accelerated 500-to 1,000-fold. A single pentasaccharide unit is sufficient to transform AT into a high binding state, which is necessary for the effective formation of the Michaelis complex between AT and FXa. Similar to all serpins, AT contains a flexible reactive center loop (RCL) with a scissile bond (Arg393-Ser394) at the C-terminal part. The target protease cleaves this bond and then it becomes covalently captured by the inhibitor. Part of the antithrombin RCL is entrapped and minimally available for interaction with its potential targets. The binding of pentasaccharide or heparin-containing pentasaccharide units to the N-terminal part of the molecule induces the expulsion of RCL from its entrapped position.
AT is an essential thromboprotective molecule; its lack is incompatible with life. Quantitative AT deficiency (type I) and most qualitative (type II) deficiencies exist only in heterozygous form. The cumulative prevalence of AT deficiencies in the general population is estimated to be between 1 in 2,000 and 1 in 5,000, 4,5 whereas among patients with venous thromboembolism (VTE), its frequency is between 1 in 20 and 1 in 200. 6, 7 AT deficiency also represents an increased risk for the development of pulmonary embolism and for the recurrence of VTE. Control, Potter Bar, England) was used as calibrator. AT determination was carried out at least 3 months apart from the thrombotic events. Among the recruited patients, seven had type I defect, one had type II PE, and 29 patients had type II HBS deficiency. The third group represented 20 families. Among type II HBS-deficient patients nine carried the mutation in homozygous form, while 20 patients were heterozygotes Table 1 .
Results
The two anti-FXa AT assays gave practically identical results with all AT-deficient patients (Table 1, Figure 1 ).
Anti-FIIa and anti-FXa results in type I-deficient patients and in the single type II PE patient (not shown in Figure   1 ) did not differ significantly; all were uniformly below 80%, the lower limit of reference interval. In contrast, with a single exception, anti-FIIa activity of type II HBS heterozygotes was in the reference interval (range, 76%-128%), whereas all anti-FXa activities in this group were below the reference interval (range, 55%-73% for the anti-FXa1 method and 46%-74% for the anti-FXa2 method). In the case of type II HBS homozygotes all anti-FIIa activities, except one, were below the reference interval (range, 48%-80%). It is to be noted that in p.Leu99Phe homozygotes,
AT antigen levels were in the lowest quartile of the reference interval or below, which suggests that the mutation, in addition to interfering with the binding of heparin, somewhat decreases the AT level. Anti-FXa activities were much lower than anti-FIIa activities; they were in the ranges of 13% to 25% and 9% to 23% using anti-FXa1 and anti- 
Discussion
The mechanism of Michaelis complex formation between FIIa and AT is somewhat different from that of FXa and AT. In the former case, the conformational change of AT induced by the allosteric effect of pentasaccharide is not 5 sufficient, and probably not even required. FIIa also binds to heparin, and the bridging effect of heparin consisting of 18 saccharide units or more is essential for the high affinity interaction between FIIa and AT. [11] [12] [13] For this reason, a mutation in the HBS might have a more profound effect on the anti-FXa than on the anti-FIIa activity of AT in the presence of heparin. In type II HBS AT deficiency, in the absence of heparin binding, AT exerts a progressive antiFXa and anti-FIIa activity. However, a much higher concentration of AT, that is, much less diluted plasma, and longer incubation time would have been needed to detect such activity. 14 The plasma is highly diluted in all assays (50-to 100-fold) and the incubation of diluted plasma with FXa in the Siemens anti-FXa assay was 180 seconds, similar to the incubation time with FIIa in the Siemens anti-FIIa assay. The incubation time in the Labexpert antiFXa assay was even shorter (60 sec). Thus, differences in the assay conditions would not be predicted to account for different sensitivities between anti-FXa and anti-FIIa assays in detecting type II HBS defect.
Heterozygous type II HBS deficiency confers a lower risk of thrombosis compared with the other subtypes. 18 An ongoing large-scale population study 6 in our laboratory seeks to establish the prevalence of this mutation in the Hungarian population and in the population of neighboring countries.
The situation might vary among different geographical areas with regard to first-line functional assay detection of AT deficiency. In the British and Spanish population, the Cambridge II mutation (p.Ala384Ser), which results in moderate thrombosis risk and a moderate decrease in AT activity, is the most prevalent cause of AT deficiency. 4, 19 Anti-FIIa AT activity assay seems to be more sensitive for the detection of Cambridge II AT defect than anti-FXa assay, although even with this assay there is an overlap between controls and heterozygotes. 19, 20 The diagnosis of Cambridge II deficiency could be reliably established only by means of molecular genetic methods.
Twelve type II HBS AT mutations have been reported in the AT mutation database 
